

Paul A Northcott

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2979404/publications.pdf>

Version: 2024-02-01

163
papers

39,616
citations

6613

79
h-index

5679

162
g-index

169
all docs

169
docs citations

169
times ranked

40880
citing authors

#	ARTICLE	IF	CITATIONS
1	Signatures of mutational processes in human cancer. <i>Nature</i> , 2013, 500, 415-421.	27.8	8,060
2	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
3	Molecular subgroups of medulloblastoma: the current consensus. <i>Acta Neuropathologica</i> , 2012, 123, 465-472.	7.7	1,536
4	Medulloblastoma Comprises Four Distinct Molecular Variants. <i>Journal of Clinical Oncology</i> , 2011, 29, 1408-1414.	1.6	1,131
5	The landscape of genomic alterations across childhood cancers. <i>Nature</i> , 2018, 555, 321-327.	27.8	1,068
6	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. <i>Acta Neuropathologica</i> , 2012, 123, 473-484.	7.7	863
7	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	27.8	787
8	Dissecting the genomic complexity underlying medulloblastoma. <i>Nature</i> , 2012, 488, 100-105.	27.8	765
9	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	27.8	761
10	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. <i>Cell</i> , 2012, 148, 59-71.	28.9	743
11	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
12	Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. <i>Nature</i> , 2012, 488, 106-110.	27.8	675
13	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. <i>Nature Genetics</i> , 2013, 45, 927-932.	21.4	674
14	The Genetic Landscape of the Childhood Cancer Medulloblastoma. <i>Science</i> , 2011, 331, 435-439.	12.6	652
15	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. <i>Cancer Cell</i> , 2013, 24, 660-672.	16.8	633
16	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothed Inhibition. <i>Cancer Cell</i> , 2014, 25, 393-405.	16.8	627
17	Medulloblastomics: the end of the beginning. <i>Nature Reviews Cancer</i> , 2012, 12, 818-834.	28.4	560
18	Enhancer hijacking activates GF11 family oncogenes in medulloblastoma. <i>Nature</i> , 2014, 511, 428-434.	27.8	520

#	ARTICLE	IF	CITATIONS
19	Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. <i>Cancer Cell</i> , 2011, 20, 143-157.	16.8	494
20	Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. <i>Acta Neuropathologica</i> , 2016, 131, 821-831.	7.7	478
21	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <i>Cancer Cell</i> , 2016, 29, 379-393.	16.8	438
22	Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma. <i>Nature Genetics</i> , 2009, 41, 465-472.	21.4	391
23	Subgroup-Specific Prognostic Implications of <i>TP53</i> Mutation in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2927-2935.	1.6	381
24	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. <i>Nature</i> , 2014, 510, 537-541.	27.8	378
25	Clonal selection drives genetic divergence of metastatic medulloblastoma. <i>Nature</i> , 2012, 482, 529-533.	27.8	376
26	Medulloblastoma. <i>Nature Reviews Disease Primers</i> , 2019, 5, 11.	30.5	376
27	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. <i>Cell</i> , 2013, 153, 1064-1079.	28.9	348
28	YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation. <i>Genes and Development</i> , 2009, 23, 2729-2741.	5.9	332
29	Pan-cancer analysis of somatic copy-number alterations implicates <i>IRS4</i> and <i>IGF2</i> in enhancer hijacking. <i>Nature Genetics</i> , 2017, 49, 65-74.	21.4	326
30	Cross-species genomics matches driver mutations and cell compartments to model ependymoma. <i>Nature</i> , 2010, 466, 632-636.	27.8	324
31	Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. <i>Acta Neuropathologica</i> , 2012, 123, 615-626.	7.7	318
32	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. <i>Nature</i> , 2016, 530, 57-62.	27.8	318
33	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	10.7	307
34	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. <i>Acta Neuropathologica</i> , 2015, 129, 669-678.	7.7	277
35	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
36	The miR-17/92 Polycistron Is Up-regulated in Sonic Hedgehog-Driven Medulloblastomas and Induced by N-myc in Sonic Hedgehog-Treated Cerebellar Neural Precursors. <i>Cancer Research</i> , 2009, 69, 3249-3255.	0.9	273

#	ARTICLE	IF	CITATIONS
37	Resolving medulloblastoma cellular architecture by single-cell genomics. <i>Nature</i> , 2019, 572, 74-79.	27.8	273
38	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. <i>Lancet Oncology</i> , The, 2018, 19, 785-798.	10.7	268
39	An Animal Model of MYC-Driven Medulloblastoma. <i>Cancer Cell</i> , 2012, 21, 155-167.	16.8	267
40	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	27.8	266
41	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	1.6	263
42	The clinical implications of medulloblastoma subgroups. <i>Nature Reviews Neurology</i> , 2012, 8, 340-351.	10.1	261
43	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. <i>Acta Neuropathologica</i> , 2013, 126, 907-915.	7.7	254
44	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. <i>Acta Neuropathologica</i> , 2013, 125, 913-916.	7.7	244
45	Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. <i>Nature Communications</i> , 2015, 6, 7391.	12.8	244
46	Quiescent Sox2+ Cells Drive Hierarchical Growth and Relapse in Sonic Hedgehog Subgroup Medulloblastoma. <i>Cancer Cell</i> , 2014, 26, 33-47.	16.8	241
47	MicroRNA-199b-5p Impairs Cancer Stem Cells through Negative Regulation of HES1 in Medulloblastoma. <i>PLoS ONE</i> , 2009, 4, e4998.	2.5	233
48	Adult Medulloblastoma Comprises Three Major Molecular Variants. <i>Journal of Clinical Oncology</i> , 2011, 29, 2717-2723.	1.6	215
49	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. <i>Acta Neuropathologica</i> , 2011, 122, 231-240.	7.7	195
50	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. <i>Acta Neuropathologica</i> , 2014, 128, 279-289.	7.7	191
51	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. <i>Acta Neuropathologica</i> , 2019, 138, 309-326.	7.7	180
52	Distinct Neural Stem Cell Populations Give Rise to Disparate Brain Tumors in Response to N-MYC. <i>Cancer Cell</i> , 2012, 21, 601-613.	16.8	177
53	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. <i>Clinical Cancer Research</i> , 2010, 16, 3240-3252.	7.0	175
54	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. <i>Nature</i> , 2018, 553, 101-105.	27.8	170

#	ARTICLE	IF	CITATIONS
55	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 125, 373-384.	7.7	169
56	A Single-Cell Transcriptional Atlas of the Developing Murine Cerebellum. <i>Current Biology</i> , 2018, 28, 2910-2920.e2.	3.9	158
57	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 768-784.	10.7	151
58	Medulloblastomics revisited: biological and clinical insights from thousands of patients. <i>Nature Reviews Cancer</i> , 2020, 20, 42-56.	28.4	147
59	Pleiotropic role for <i>MYCN</i> in medulloblastoma. <i>Genes and Development</i> , 2010, 24, 1059-1072.	5.9	146
60	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	7.7	146
61	Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2018, 34, 396-410.e8.	16.8	146
62	<i>FSTL5</i> Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3852-3861.	1.6	143
63	Molecular subgroups of medulloblastoma. <i>Expert Review of Neurotherapeutics</i> , 2012, 12, 871-884.	2.8	142
64	DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies. <i>Acta Neuropathologica</i> , 2013, 125, 359-371.	7.7	133
65	Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. <i>Acta Neuropathologica</i> , 2014, 128, 137-149.	7.7	125
66	A biobank of patient-derived pediatric brain tumor models. <i>Nature Medicine</i> , 2018, 24, 1752-1761.	30.7	124
67	MLL4 Is Required to Maintain Broad H3K4me3 Peaks and Super-Enhancers at Tumor Suppressor Genes. <i>Molecular Cell</i> , 2018, 70, 825-841.e6.	9.7	123
68	Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters. <i>Journal of Clinical Oncology</i> , 2016, 34, 4151-4160.	1.6	121
69	A cell-based model system links chromothripsis with hyperploidy. <i>Molecular Systems Biology</i> , 2015, 11, 828.	7.2	118
70	Chd7 is indispensable for mammalian brain development through activation of a neuronal differentiation programme. <i>Nature Communications</i> , 2017, 8, 14758.	12.8	118
71	UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs. <i>Nature Genetics</i> , 2018, 50, 883-894.	21.4	117
72	LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). <i>Acta Neuropathologica</i> , 2012, 124, 875-881.	7.7	115

#	ARTICLE	IF	CITATIONS
73	Spatial heterogeneity in medulloblastoma. <i>Nature Genetics</i> , 2017, 49, 780-788.	21.4	112
74	Outcomes by Clinical and Molecular Features in Children With Medulloblastoma Treated With Risk-Adapted Therapy: Results of an International Phase III Trial (SJMB03). <i>Journal of Clinical Oncology</i> , 2021, 39, 822-835.	1.6	106
75	OTX2 Is Critical for the Maintenance and Progression of Shh-Independent Medulloblastomas. <i>Cancer Research</i> , 2010, 70, 181-191.	0.9	104
76	Tumour-associated macrophages exhibit anti-tumoural properties in Sonic Hedgehog medulloblastoma. <i>Nature Communications</i> , 2019, 10, 2410.	12.8	99
77	An Epigenetic Genome-Wide Screen Identifies <i>SPINT2</i> as a Novel Tumor Suppressor Gene in Pediatric Medulloblastoma. <i>Cancer Research</i> , 2008, 68, 9945-9953.	0.9	95
78	Germline <i>Elongator</i> mutations in Sonic Hedgehog medulloblastoma. <i>Nature</i> , 2020, 580, 396-401.	27.8	94
79	Children's Oncology Group Phase III Trial of Reduced-Dose and Reduced-Volume Radiotherapy With Chemotherapy for Newly Diagnosed Average-Risk Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2685-2697.	1.6	91
80	Medulloblastoma subgroups remain stable across primary and metastatic compartments. <i>Acta Neuropathologica</i> , 2015, 129, 449-457.	7.7	80
81	Personalizing the Treatment of Pediatric Medulloblastoma: Polo-like Kinase 1 as a Molecular Target in High-Risk Children. <i>Cancer Research</i> , 2013, 73, 6734-6744.	0.9	79
82	scRNA-seq in medulloblastoma shows cellular heterogeneity and lineage expansion support resistance to SHH inhibitor therapy. <i>Nature Communications</i> , 2019, 10, 5829.	12.8	77
83	Coverage Bias and Sensitivity of Variant Calling for Four Whole-genome Sequencing Technologies. <i>PLoS ONE</i> , 2013, 8, e66621.	2.5	74
84	The RNA-Binding Protein Musashi1 Affects Medulloblastoma Growth via a Network of Cancer-Related Genes and Is an Indicator of Poor Prognosis. <i>American Journal of Pathology</i> , 2012, 181, 1762-1772.	3.8	73
85	Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. <i>Neuro-Oncology</i> , 2013, 15, 1644-1651.	1.2	73
86	Next-generation (epi)genetic drivers of childhood brain tumours and the outlook for targeted therapies. <i>Lancet Oncology</i> , The, 2015, 16, e293-e302.	10.7	72
87	Targeting the enhancer of zeste homologue 2 in medulloblastoma. <i>International Journal of Cancer</i> , 2012, 131, 1800-1809.	5.1	71
88	The Genetics of Pediatric Brain Tumors. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 215-223.	4.2	69
89	Genetic and Epigenetic Inactivation of Kruppel-like Factor 4 in Medulloblastoma. <i>Neoplasia</i> , 2010, 12, 20-27.	5.3	69
90	Voltage-gated potassium channel EAG2 controls mitotic entry and tumor growth in medulloblastoma via regulating cell volume dynamics. <i>Genes and Development</i> , 2012, 26, 1780-1796.	5.9	68

#	ARTICLE	IF	CITATIONS
91	Hypermethylation of the Inactive X Chromosome Is a Frequent Event in Cancer. <i>Cell</i> , 2013, 155, 567-581.	28.9	67
92	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 515-527.	7.7	66
93	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. <i>Cancer Cell</i> , 2019, 35, 95-110.e8.	16.8	65
94	Advances in the classification of pediatric brain tumors through DNA methylation profiling: From research tool to frontline diagnostic. <i>Cancer</i> , 2018, 124, 4168-4180.	4.1	64
95	Serial assessment of measurable residual disease in medulloblastoma liquid biopsies. <i>Cancer Cell</i> , 2021, 39, 1519-1530.e4.	16.8	64
96	Role of LIM and SH3 Protein 1 (LASP1) in the Metastatic Dissemination of Medulloblastoma. <i>Cancer Research</i> , 2010, 70, 8003-8014.	0.9	62
97	Medulloblastoma-associated DDX3 variant selectively alters the translational response to stress. <i>Oncotarget</i> , 2016, 7, 28169-28182.	1.8	62
98	Inactivation of Ezh2 Upregulates Gfi1 and Drives Aggressive Myc-Driven Group 3 Medulloblastoma. <i>Cell Reports</i> , 2017, 18, 2907-2917.	6.4	61
99	Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma. <i>JAMA Oncology</i> , 2021, 7, 1313.	7.1	61
100	MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 529-538.	7.7	60
101	CXCR4 Activation Defines a New Subgroup of Sonic Hedgehog-Driven Medulloblastoma. <i>Cancer Research</i> , 2012, 72, 122-132.	0.9	58
102	Lsd1 as a therapeutic target in Gfi1-activated medulloblastoma. <i>Nature Communications</i> , 2019, 10, 332.	12.8	55
103	Silencing of Thrombospondin-1 Is Critical for Myc-Induced Metastatic Phenotypes in Medulloblastoma. <i>Cancer Research</i> , 2010, 70, 8199-8210.	0.9	54
104	Genomic and transcriptomic analyses match medulloblastoma mouse models to their human counterparts. <i>Acta Neuropathologica</i> , 2014, 128, 123-136.	7.7	54
105	Targeting Sonic Hedgehog-Associated Medulloblastoma through Inhibition of Aurora and Polo-like Kinases. <i>Cancer Research</i> , 2013, 73, 6310-6322.	0.9	52
106	NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma. <i>Cancer Cell</i> , 2018, 33, 435-449.e6.	16.8	52
107	Foretinib Is Effective Therapy for Metastatic Sonic Hedgehog Medulloblastoma. <i>Cancer Research</i> , 2015, 75, 134-146.	0.9	51
108	FISH and chips: the recipe for improved prognostication and outcomes for children with medulloblastoma. <i>Cancer Genetics</i> , 2011, 204, 577-588.	0.4	50

#	ARTICLE	IF	CITATIONS
109	Germline <i>GPR161</i> Mutations Predispose to Pediatric Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 43-50.	1.6	50
110	Genomics of medulloblastoma: from Giemsa-banding to next-generation sequencing in 20 years. <i>Neurosurgical Focus</i> , 2010, 28, E6.	2.3	48
111	DDX3X Suppresses the Susceptibility of Hindbrain Lineages to Medulloblastoma. <i>Developmental Cell</i> , 2020, 54, 455-470.e5.	7.0	47
112	Patient-derived orthotopic xenografts of pediatric brain tumors: a St. Jude resource. <i>Acta Neuropathologica</i> , 2020, 140, 209-225.	7.7	45
113	Functional Genomics Identifies Drivers of Medulloblastoma Dissemination. <i>Cancer Research</i> , 2012, 72, 4944-4953.	0.9	44
114	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. <i>Acta Neuropathologica</i> , 2021, 141, 771-785.	7.7	44
115	The Shh Receptor Boc Promotes Progression of Early Medulloblastoma to Advanced Tumors. <i>Developmental Cell</i> , 2014, 31, 34-47.	7.0	43
116	Phase II Study of Nonmetastatic Desmoplastic Medulloblastoma in Children Younger Than 4 Years of Age: A Report of the Children's Oncology Group (ACNS1221). <i>Journal of Clinical Oncology</i> , 2020, 38, 223-231.	1.6	40
117	Deconstructing Sonic Hedgehog Medulloblastoma: Molecular Subtypes, Drivers, and Beyond. <i>Trends in Genetics</i> , 2021, 37, 235-250.	6.7	40
118	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	1.6	40
119	Medulloblastoma genomics in the modern molecular era. <i>Brain Pathology</i> , 2020, 30, 679-690.	4.1	39
120	The Epigenetics of Brain Tumors. <i>Methods in Molecular Biology</i> , 2012, 863, 139-153.	0.9	38
121	Gliomatosis cerebri in children shares molecular characteristics with other pediatric gliomas. <i>Acta Neuropathologica</i> , 2016, 131, 299-307.	7.7	38
122	DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. <i>Acta Neuropathologica</i> , 2017, 134, 965-967.	7.7	38
123	Mouse models of medulloblastoma. <i>Chinese Journal of Cancer</i> , 2011, 30, 442-449.	4.9	38
124	Tuberous Sclerosis Complex Suppression in Cerebellar Development and Medulloblastoma: Separate Regulation of Mammalian Target of Rapamycin Activity and p27Kip1 Localization. <i>Cancer Research</i> , 2009, 69, 7224-7234.	0.9	37
125	The Role of Chromatin Remodeling in Medulloblastoma. <i>Brain Pathology</i> , 2013, 23, 193-199.	4.1	37
126	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 174.	5.2	37

#	ARTICLE	IF	CITATIONS
127	Risk-adapted therapy and biological heterogeneity in pineoblastoma: integrated clinico-pathological analysis from the prospective, multi-center SJMB03 and SJYC07 trials. <i>Acta Neuropathologica</i> , 2020, 139, 259-271.	7.7	36
128	Proteomic analysis of Medulloblastoma reveals functional biology with translational potential. <i>Acta Neuropathologica Communications</i> , 2018, 6, 48.	5.2	35
129	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	7.7	34
130	Normal and oncogenic roles for microRNAs in the developing brain. <i>Cell Cycle</i> , 2009, 8, 4049-4054.	2.6	30
131	Subgroup-specific alternative splicing in medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 485-499.	7.7	28
132	Patient-derived models recapitulate heterogeneity of molecular signatures and drug response in pediatric high-grade glioma. <i>Nature Communications</i> , 2021, 12, 4089.	12.8	27
133	Canonical $TGF\beta^2$ Pathway Activity Is a Predictor of SHH-Driven Medulloblastoma Survival and Delineates Putative Precursors in Cerebellar Development. <i>Brain Pathology</i> , 2013, 23, 178-191.	4.1	26
134	Bithalamic gliomas may be molecularly distinct from their unilateral high-grade counterparts. <i>Brain Pathology</i> , 2018, 28, 112-120.	4.1	26
135	Large 1p36 Deletions Affecting Arid1a Locus Facilitate Mycn-Driven Oncogenesis in Neuroblastoma. <i>Cell Reports</i> , 2020, 30, 454-464.e5.	6.4	26
136	Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream. <i>Journal of Clinical Oncology</i> , 2017, 35, 2346-2354.	1.6	25
137	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. <i>Cell Reports Medicine</i> , 2020, 1, 100038.	6.5	24
138	PCDH10 is a candidate tumour suppressor gene in medulloblastoma. <i>Child's Nervous System</i> , 2011, 27, 1243-1249.	1.1	21
139	MyoD Is a Tumor Suppressor Gene in Medulloblastoma. <i>Cancer Research</i> , 2013, 73, 6828-6837.	0.9	21
140	Norrin/Frizzled4 signalling in the preneoplastic niche blocks medulloblastoma initiation. <i>ELife</i> , 2016, 5, .	6.0	21
141	Proteomic profiling of high risk medulloblastoma reveals functional biology. <i>Oncotarget</i> , 2015, 6, 14584-14595.	1.8	20
142	Medulloblastoma uses GABA transaminase to survive in the cerebrospinal fluid microenvironment and promote leptomeningeal dissemination. <i>Cell Reports</i> , 2021, 35, 109302.	6.4	19
143	Deep Sequencing Identifies IDH1 R132S Mutation in Adult Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, e27-e31.	1.6	18
144	SWI/SNF complex heterogeneity is related to polyphenotypic differentiation, prognosis, and immune response in rhabdoid tumors. <i>Neuro-Oncology</i> , 2020, 22, 785-796.	1.2	18

#	ARTICLE	IF	CITATIONS
145	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. <i>Acta Neuropathologica</i> , 2018, 135, 635-638.	7.7	17
146	Functional loss of a noncanonical BCOR-PRC1.1 complex accelerates SHH-driven medulloblastoma formation. <i>Genes and Development</i> , 2020, 34, 1161-1176.	5.9	16
147	The HHIP-AS1 lncRNA promotes tumorigenicity through stabilization of dynein complex 1 in human SHH-driven tumors. <i>Nature Communications</i> , 2022, 13, .	12.8	16
148	Intertumoral and Intratumoral Heterogeneity as a Barrier for Effective Treatment of Medulloblastoma. <i>Neurosurgery</i> , 2013, 60, 57-63.	1.1	13
149	Aberrant immunostaining pattern of the CD24 glycoprotein in clinical samples and experimental models of pediatric medulloblastomas. <i>Journal of Neuro-Oncology</i> , 2015, 123, 1-13.	2.9	13
150	Keeping it real to kill glioblastoma. <i>Nature</i> , 2017, 547, 291-292.	27.8	13
151	Vorinostat and isotretinoin with chemotherapy in young children with embryonal brain tumors: A report from the Pediatric Brain Tumor Consortium (PBTC-026). <i>Neuro-Oncology</i> , 2022, 24, 1178-1190.	1.2	13
152	Bridging the treatment gap in infant medulloblastoma: molecularly informed outcomes of a globally feasible regimen. <i>Neuro-Oncology</i> , 2020, 22, 1873-1881.	1.2	12
153	Circulating tumor DNA profiling for childhood brain tumors: Technical challenges and evidence for utility. <i>Laboratory Investigation</i> , 2022, 102, 134-142.	3.7	11
154	Calculating a cure for cancer: managing medulloblastoma MATH1-atically. <i>Expert Review of Neurotherapeutics</i> , 2010, 10, 1489-1492.	2.8	7
155	WNT-activated embryonal tumors of the pineal region: ectopic medulloblastomas or a novel pineoblastoma subgroup?. <i>Acta Neuropathologica</i> , 2020, 140, 595-597.	7.7	7
156	Depletion of kinesin motor KIF20A to target cell fate control suppresses medulloblastoma tumour growth. <i>Communications Biology</i> , 2021, 4, 552.	4.4	5
157	A genetic mouse model with postnatal <i>Nf1</i> and <i>p53</i> loss recapitulates the histology and transcriptome of human malignant peripheral nerve sheath tumor. <i>Neuro-Oncology Advances</i> , 2021, 3, v129.	0.7	3
158	Revised clinical and molecular risk strata define the incidence and pattern of failure in medulloblastoma following risk-adapted radiotherapy and dose-intensive chemotherapy: results from a phase III multi-institutional study. <i>Neuro-Oncology</i> , 2022, 24, 1166-1175.	1.2	2
159	Low-coverage whole-genome sequencing of cerebrospinal-fluid-derived cell-free DNA in brain tumor patients. <i>STAR Protocols</i> , 2022, 3, 101292.	1.2	2
160	MEDB-69. Clinical and molecular meta-analysis of three major medulloblastoma clinical trials (ACNS0331, SJMB03, ACNS0332) uncovers novel strategies to improve risk-stratified therapy. <i>Neuro-Oncology</i> , 2022, 24, i122-i122.	1.2	1
161	MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. <i>Neuro-Oncology</i> , 2022, 24, i124-i125.	1.2	1
162	BIOM-36. SERIAL ASSESSMENT OF MEASURABLE RESIDUAL DISEASE IN MEDULLOBLASTOMA LIQUID BIOPSIES. <i>Neuro-Oncology</i> , 2021, 23, vi18-vi19.	1.2	0

#	ARTICLE	IF	CITATIONS
163	INSP-09. Using genetically engineered mouse models and patient-derived orthotopic xenografts to develop new therapies for pediatric brain tumors.. Neuro-Oncology, 2022, 24, i188-i188.	1.2	0